Amgen amends Aimovig collaboration with Novartis, ends US royalties and cost-sharing

AMGEN INC

Novartis gets sole commercialization rights for Aimovig outside US and Japan; Amgen ends royalty payments on US sales.
U.S. Collaboration Agreement terminated Jan 31, 2022; parties no longer share US commercialization costs.
Amgen's share of Franchise Product 1 (Aimovig) development costs capped at $[***] aggregate; thereafter split 50/50.
Litigation between the parties resolved concurrently with these amendments.
Novartis to fund US Medical Affairs activities until a defined completion date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.